Bayesian morphological peak estimation and its application to chromosome counting via fluorescence In situ hybridization

1996 ◽  
Vol 29 (6) ◽  
pp. 987-996 ◽  
Author(s):  
Edward R. Dougherty ◽  
Yidong Chen ◽  
Amir Waks
2006 ◽  
Vol 175 (4S) ◽  
pp. 287-288 ◽  
Author(s):  
Juliann M. Dziubinski ◽  
Michael F. Sarosdy ◽  
Paul R. Kahn ◽  
Mark D. Ziffer ◽  
William R. Love ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 156-156
Author(s):  
Chandler D. Dora ◽  
Yasushi Kondo ◽  
Fusheng X. Lan ◽  
Jeffrey M. Slezak ◽  
Erik J. Bergstralh ◽  
...  

2014 ◽  
pp. 15-20
Author(s):  
Van Huy Tran ◽  
Thi Minh Thi Ha ◽  
Trung Nghia Van ◽  
Viet Nhan Nguyen ◽  
Phan Tuong Quynh Le ◽  
...  

Background: HER-2/neu is a predictive biomarker for treatment of gastric cancer using trastuzumab in combination with chemotherapy. This study aimed to evaluate the status of HER-2/neu gene amplification using fluorescence in situ hybridization (FISH) in gastric cancer. Patients and methods: thirty six gastric cancer patients were assessed HER-2/neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit (including HER-2/neu probe and CEP-17 probe) with biopsy and surgical specimens. Results: The HER-2/neu gene amplification was observed in three cases (8.3%), the HER-2/neu gene amplification rate in Lauren’s intestinal-type and diffuse-type were 11.8% and 5.2%, respectively. Conclusion: We applied successfully FISH technique with gastric cancer tissue samples. This technique could be performed as routine test in gastric cancer in order to select patients that benefit from trastuzumab in combination with chemotherapy.


Sign in / Sign up

Export Citation Format

Share Document